Aspen Releases 2014 Loss Development Triangles

HAMILTON, Bermuda--(BUSINESS WIRE)-- Aspen Insurance Holdings Limited (“Aspen”) (NYSE: AHL) has published its 2014 Loss Development Triangles (the “Loss Triangles”) on its website within the Investor Relations section.

The Loss Triangles provide stakeholders with additional insight into the reserves held on Aspen’s balance sheet as at December 31, 2014. They present eight reserving lines of business which fall within Aspen’s two reporting segments, Insurance and Reinsurance.

The Loss Triangles provide data on earned premiums, paid losses, case reserves and incurred losses on an accident year basis on a gross, ceded and net basis. They also include total incurred but not reported (IBNR) reserves as at December 31, 2014, both gross and net of applicable reinsurance, together with development triangles for paid and incurred losses on a gross basis.

About Aspen Insurance Holdings Limited

Aspen provides reinsurance and insurance coverage to clients in various domestic and global markets through wholly-owned subsidiaries and offices in Bermuda, France, Germany, Ireland, Singapore, Switzerland, the United Kingdom and the United States. For the year ended December 31, 2014, Aspen reported $10.7 billion in total assets, $4.8 billion in gross reserves, $3.4 billion in total shareholders’ equity and $2.9 billion in gross written premiums. Its operating subsidiaries have been assigned a rating of “A” (“Strong”) by Standard & Poor’s Financial Services, an “A” (“Excellent”) by A.M. Best Company Inc. and an “A2” (“Good”) by Moody’s Investor Service, Inc.

Application of the Safe Harbor of the Private Securities Litigation Reform Act of 1995

This press release may contain written “forward-looking statements” within the meaning of the U.S. federal securities laws. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “expect,” “assume,” “objective,” “target,” “intend,” “plan,” “believe,” “do not believe,” “project,” “anticipate,” “seek,” “will,” “likely,” “estimate,” “may,” “guidance,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “aim,” “continue,” “on track” and similar expressions of a future or forward-looking nature.

All forward-looking statements rely on a number of assumptions, estimates and data concerning future results and events and are subject to a number of uncertainties and other factors, many of which are outside Aspen’s control that could cause actual results to differ materially from such statements. For a detailed description of uncertainties and other factors that could impact the forward-looking statements in this press release, please see the “Risk Factors” section in Aspen’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the U.S. Securities and Exchange Commission on February 23, 2015. Aspen undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150908005817/en/

Aspen
Please visit www.aspen.co or contact:
Aspen
Investors
Mark Jones, +1-646-289-4945
Senior Vice President, Investor Relations
[email protected]
or
Media
Steve Colton, +44 20 7184 8337
Group Head of Communications
[email protected]
or
International – Citigate Dewe Rogerson
Caroline Merrell or Jos Bieneman, +44 20 7638 9571
[email protected]
[email protected]
or
North America – Abernathy MacGregor
Carina Davidson or Allyson Vento, +1-212-371-5999
[email protected]
[email protected]

Source: Aspen Insurance Holdings Limited

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Viking Therapeutics names Hubert Chen as chief medical officer
• Purple Biotech presents IM1240 preclinical data at EACR conference
• PureCycle prices $395 million dual offering of convertible notes and stock